French biotech EG 427 has had success with its urinary incontinence DNA therapy, EG110A, showing a more than 80% reduction in episodes.
In the Phase Ib/IIa trial (NCT06596291), the lowest dose of EG110A was found to reduce the incidence of urinary incontinence episodes by over 88% by week 12, with the effect already clearly established at week four. The drug is being investigated for the treatment of neurogenic detrusor overactivity (NDO) in people with spinal cord injury (SCI), a disorder in which urinary incontinence is the main symptom.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The company added that EG110A demonstrated a good safety profile, and dosing in the second cohort has started.
EG 427 CEO Dr Philippe Chambon said: “For EG 427, as these validate a biological mechanism underpinning multiple diseases driven by type C sensory neuron activity, we can now envision developing EG110A more broadly in clinical studies in multiple underserved pathologies, including in the pain field.”
Chambon adds that the data validates the company’s proprietary HERMES nrHSV-1 technology platform, which has been used to discover EG142A and two other disclosed therapies.
EG110A is a non-replicating HSV-1 vector designed to selectively silence the signals of type C sensory neurons responsible for the bladder muscle overactivity, whilst preserving other bladder controls. Patients receive a single treatment course consisting of multiple intradetrusor injections.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataEG 427 is not the first company to investigate a non-replicating herpes vector product. In 2023, Krystal Biotech received FDA’s approval for its gene therapy Vyjuvek to treat dystrophic epidermolysis bullosa (DEB).
NDO is a common urinary bladder dysfunction caused by SCI and other neurodegenerative diseases such as multiple sclerosis (MS) or Parkinson’s disease. NDO causes uncontrolled urinary incontinence, risk of kidney damage and urinary tract infections (UTIs) that can lead to death in 5%-10% of the SCI population. Altogether, NDO affects at least two million patients suffering from SCI, MS, Parkinson’s and other neurodegenerative diseases, across the seven major markets (7MM: US, France, Germany, Italy, Spain, the UK, and Japan).
Standard of care for patients with NDS is anticholinergic medications and intermittent catheterisation (CIC). If these therapies are unsuccessful, patients may receive botulinum toxin A (BTX-A) injections or undergo bladder augmentation, a surgical procedure involving enlarging the bladder with a segment of bowel.
Cell & Gene therapy coverage on Clinical Trials Arena is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
